Publicaciones en las que colabora con Francisco Javier González Barcala (12)

2023

  1. A Study of the Prevalence of Asthma in the General Population in Spain

    Open Respiratory Archives, Vol. 5, Núm. 2

  2. Serum exosome inflamma-miRs are surrogate biomarkers for asthma phenotype and severity

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 1, pp. 141-155

  3. Treatment Patterns of Monoclonal Antibodies in Patients With Severe Uncontrolled Asthma Treated by Pulmonologists in Spain

    Open Respiratory Archives, Vol. 5, Núm. 3

  4. What's New in the 2022 Consensus for Severe Asthma in Adults

    Archivos de Bronconeumologia

2022

  1. Consensus document for severe asthma in adults. 2022 update

    Open Respiratory Archives, Vol. 4, Núm. 3

  2. FENO measurement devices

    Open Respiratory Archives, Vol. 4, Núm. 4

  3. Monoclonal antibody treatment for severe uncontrolled asthma in Spain: analytical map

    Journal of Asthma, Vol. 59, Núm. 10, pp. 1997-2007

2021

  1. Biologics in Asthma: Don't Let the Magic Bullets Sink the Boat

    Archivos de Bronconeumologia

  2. Correction to: REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study (Drugs, (2021), 81, 15, (1763-1774), 10.1007/s40265-021-01597-9)

    Drugs

  3. Efficacy of mepolizumab in usual clinical practice and characteristics of responders: Mepolizumab in usual clinical practice

    Respiratory Medicine, Vol. 187

  4. REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study

    Drugs, Vol. 81, Núm. 15, pp. 1763-1774

2017

  1. Concordance of opinions between patients and physicians and their relationship with symptomatic control and future risk in patients with moderate-severe asthma

    BMJ Open Respiratory Research, Vol. 4, Núm. 1